Related Experiment Video

Updated: Jun 23, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Drug therapy of cardiac diseases in children

1, Anita Saxena, Rajnish Juneja

  • 1All India Institute of Medical Sciences, New Delhi 110029, India. anitasaxena@hotmail.com

Indian Pediatrics
|April 23, 2009
PubMed

Insights

New guidelines address pediatric cardiology drug use, offering specific recommendations for heart failure, hypertension, and thrombosis in children. These evidence-based guidelines ensure safer and more effective treatment for pediatric heart conditions.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Evidence-Based Medicine

Background:

  • Current pediatric cardiac drug use relies heavily on adult data.
  • Significant differences in neonates, infants, and children necessitate distinct guidelines.
  • Metabolic clearance variations impact drug efficacy and safety in pediatric populations.

Purpose of the Study:

  • To develop evidence-based guidelines for pediatric cardiology drug indications and dosing.
  • To outline adverse effects and safety profiles of commonly used pediatric cardiac drugs.
  • To create treatment algorithms for diverse pediatric cardiovascular clinical scenarios.

Main Methods:

  • Expert deliberations at the National Meeting on Management of Congenital Heart Diseases in India.
  • Consensus review of existing literature.
  • Supported by the Pediatric Cardiac Society of India.

Main Results:

  • Recommendations established for drugs treating pediatric heart failure, hypertension, and thrombosis.
  • Guidelines provided for supraventricular tachycardia and intensive care unit drug management.
  • Specific guidance issued for intravenous immunoglobulins and sildenafil in children.

Conclusions:

  • Evidence-based guidelines are now available for critical pediatric cardiology drug applications.
  • These guidelines aim to improve treatment protocols for pediatric heart conditions.
  • The recommendations address a crucial gap in pediatric cardiovascular pharmacotherapy.
Abstract

More Related Videos

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...